Challenging the standard in early-stage ovarian cancer: current evidence and a standardized framework for sentinel...

Sentinel lymph node (SLN) mapping is being explored as a less invasive alternative to systematic lymphadenectomy in early-stage epithelial ovarian cancer. Existing evidence, mainly from feasibility and diagnostic accuracy studies, shows that SLN detection by mapping is achievable, but results remain inconsistent due to heterogeneity in methodology. Detection rates of SLN vary widely across studies, influenced by tracer type, injection technique, timing, and the extent of pathological assessment. Dual-tracer protocols combining radiotracers and indocyanine green generally yield higher detection rates than single tracers do, while injection into both infundibulopelvic and utero-ovarian ligaments yields adequate coverage of para-aortic and pelvic regions. However, detection of pelvic SLNs remains limited. In this context, cervical injection has been proposed as an alternative, with preliminary data showing enhanced pelvic lymph node detection. As for injection timing, pre-adnexectomy injection preserves native lymphatics but is technically demanding; post-adnexectomy injection is technically easier and more widely used. While ultra-staging enhances diagnostic sensitivity, its clinical implications for detecting micro-metastases and isolated tumor cells in epithelial ovarian cancer are still undefined and require further investigation. To support safe and standardized research-based implementation, we propose a unified framework that integrates levels of evidence with grades of recommendation across each procedural domain. This structured approach provides a foundation for protocol development, prospective data collection, and future clinical trials, aiming to bridge the gap between experimental mapping and potential clinical integration in early-stage epithelial ovarian cancer.